Treatment Discontinuation in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease - PubMed
4 hours ago
- #treatment discontinuation
- #relapse risk
- #MOGAD
- The study examines the relapse risk after treatment discontinuation in adult patients with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).
- A retrospective cohort study was conducted using data from 41 centers in the French NOMADMUS database, involving 705 patients who met inclusion criteria.
- Among 319 patients who received maintenance therapy, 83 discontinued treatment either due to scheduled reasons (65.1%) or adverse events (34.9%).
- After discontinuation, 7 patients relapsed, with a median time to relapse of 0.5 years, and the cumulative incidence of relapse at 1 year was 8.7%.
- Relapses were mild, with minimal changes in disability scores, and factors increasing relapse risk included treatment duration less than 1 year and less than 2 years since the last relapse.
- The findings suggest that discontinuing treatment may be safe for selected adult MOGAD patients, but further clinical trials are needed to confirm these results and establish guidelines.